Description
DK
Dr. Daria Kwaśniewska
ESMO Certified Consultant Medical Oncologist
Reviewed June 2026
⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription is mandatory before any order is processed.
Is Palbocent 125 mg right for your situation?
Review these criteria with your oncologist before enquiring✔ You may be a candidate if
- ✓Diagnosed with HR-positive, HER2-negative advanced or metastatic breast cancer
- ✓Postmenopausal, or premenopausal with ovarian suppression, starting combination endocrine therapy
- ✓Need a WHO-GMP generic alternative to Ibrance® made by Incepta
- ✓Hold a valid oncologist prescription
✖ May NOT be suitable if
- ✗HR-negative or HER2-positive breast cancer (different treatment pathway entirely)
- ✗Severe pre-existing neutropenia or active severe infection
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Severe hepatic impairment without oncologist dose adjustment
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Palbocent 125 mg?
Palbocent 125 mg is a generic formulation of Palbociclib — a CDK4/6 inhibitor — manufactured by Incepta Pharmaceuticals Ltd., one of Bangladesh’s largest and most established pharmaceutical manufacturers. Each capsule contains 125 mg of palbociclib, the same active molecule found in Ibrance® (Pfizer), and is dispensed under the Named Patient Program for patients requiring an affordable, quality-assured alternative.
Palbociclib is always used in combination with hormone (endocrine) therapy — it is not approved or effective as a standalone treatment.
| Generic name | Palbociclib |
| Reference brand | Ibrance® (Pfizer) |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | CDK4/6 Inhibitor |
| Dosage form | Capsule — 125 mg |
| Pack size | 21 capsules per pack |
| Route | Oral · once daily, 21 days on / 7 days off |
| Prescription | Required — oncologist only |
How Palbociclib Works
HR-positive breast cancer cells rely on oestrogen signalling to drive a protein pair called cyclin D1-CDK4/6, which propels them through the cell division cycle. Palbociclib selectively inhibits CDK4 and CDK6, blocking cancer cells at the G1 checkpoint before they can replicate.
Hormone therapy reduces the oestrogen signal that drives cancer growth, while palbociclib independently blocks the cell-cycle machinery the cancer needs to divide — a two-pronged synergistic approach. In the PALOMA-2 trial, adding palbociclib to letrozole more than doubled median progression-free survival versus letrozole alone (24.8 vs 14.5 months). NCCN guidelines list palbociclib combinations as a Category 1 preferred regimen for HR-positive, HER2-negative metastatic breast cancer. View NCCN Breast Cancer Guidelines →
What to Expect: First 30 Days
Palbociclib follows a 28-day cycle structure — understanding the pattern helps you anticipate blood test timing and what symptoms to expect.
- Days 1–14: Your white blood cell count, especially neutrophils, typically begins to fall — this is expected and closely monitored. A blood test is usually scheduled around day 14 of your first two treatment cycles.
- Days 15–21: Continue daily dosing through day 21. Mild fatigue or nausea may emerge. Blood counts typically reach their lowest point around this window before beginning to recover.
- Days 22–28 (off period): A mandatory 7-day pause allows bone marrow and blood counts to recover before the next cycle begins. This off-period is a built-in safety feature of the regimen — do not skip it.
Side Effects
The most clinically significant effect of palbociclib is suppression of white blood cells (neutropenia), making frequent blood monitoring mandatory, particularly in the first two cycles.
Common · Usually Manageable
- Neutropenia (low white blood cell count)
- Fatigue and weakness
- Nausea and mouth sores
- Hair thinning
- Diarrhoea
- Decreased appetite
- Numbness or tingling in hands/feet
Serious · Report Immediately
- Febrile neutropenia (fever with low white cells)
- Interstitial lung disease / pneumonitis
- Severe infections
- Significant liver enzyme elevation
- Severe, persistent diarrhoea or vomiting
⚠ Call your doctor immediately if you experience:
- Fever of 38°C (100.4°F) or higher — especially while neutrophil counts are low
- New or worsening breathlessness, dry cough, or chest pain
- Signs of infection: chills, sore throat, worsening mouth sores, or burning urination
How to Take Palbocent 125 mg
Standard dose: 1 capsule (125 mg) once daily for 21 consecutive days, followed by 7 days off — a complete 28-day cycle. Taken together with your prescribed hormone therapy.
- 1Once daily for 21 days, then 7 days off — track the cycle carefully using a calendar; consistent tracking helps both you and your care team.
- 2Take with food — food improves absorption and reduces nausea. Avoid grapefruit and grapefruit juice entirely (CYP3A4 interaction).
- 3Swallow capsules whole with a full glass of water. Do not open, crush, or chew.
- 4If you miss a dose or vomit shortly after taking one, do not take an additional dose — resume at the next scheduled time.
- 5Storage: below 30°C, protected from moisture and light, out of reach of children.
Caregiver Guidance
- ♥Watch for fever closely, especially days 10–21 — neutrophil counts are typically lowest during this window. Any temperature of 38°C or higher needs immediate medical contact — treat it as a possible emergency, not something to wait out.
- ♥Help track the 28-day cycle — mark dosing days and the 7-day off period clearly on a calendar or in an app. Missing this schedule is a common and entirely avoidable error.
- ♥Support infection precautions — encourage hand hygiene, avoid crowded indoor spaces when counts are low, and ensure all scheduled blood tests are kept.
If the Medicine Stops Working
Resistance to CDK4/6 inhibitors like palbociclib can develop through loss of Rb (retinoblastoma protein) function, CDK6 amplification, or activation of alternative growth pathways (such as PI3K/AKT/mTOR or FGFR signalling). When disease progresses on palbocent, your oncologist will typically consider switching the endocrine partner (e.g. to fulvestrant), adding a PI3K inhibitor if a PIK3CA mutation is identified on testing, or moving to chemotherapy depending on disease burden and prior treatment history. Repeat tumour profiling at progression often guides this next-step decision.
Frequently Asked Questions
Why do I need blood tests so often on this medicine?
Palbociclib reduces white blood cell counts (specifically neutrophils) in the majority of patients. Frequent blood monitoring — especially in the first two cycles, typically at the start of each cycle and around day 14 — allows your oncologist to catch and manage neutropenia before it becomes dangerous.
Can Palbocent be used alone, without hormone therapy?
No. Palbociclib is approved and clinically effective only in combination with endocrine (hormone) therapy — either an aromatase inhibitor (such as letrozole) or fulvestrant. It is not used as a standalone treatment. Your oncologist will prescribe the specific hormone therapy partner appropriate for your situation.
What is the difference between Palbocent, Palboxen, and Palbonix?
All three are 125 mg palbociclib capsules with identical active ingredients and mechanism. The distinction is the manufacturer: Palbocent is made by Incepta Pharmaceuticals, Palboxen by Everest Pharmaceuticals, and Palbonix by Beacon Pharmaceuticals. All are WHO-GMP certified and dispensed under the Named Patient Program. Availability may vary by region — contact us to confirm current stock.
Will I lose my hair on Palbocent?
Mild to moderate hair thinning is a recognised side effect of palbociclib, but complete hair loss (alopecia) as seen with traditional chemotherapy is uncommon. Most patients experience gradual thinning rather than dramatic loss. Discuss any significant hair changes with your oncologist.
Can I take Palbocent with my other medications?
Palbociclib is metabolised via the CYP3A4 enzyme pathway. Strong CYP3A4 inhibitors (certain antifungals, some antibiotics) can increase palbociclib levels, while strong inducers (rifampicin, St John’s Wort) can reduce its effectiveness. Avoid grapefruit entirely. Always provide your full medication list to your oncologist and pharmacist before starting.
How do I order Palbocent through Meds For Cancer?
Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription. Our team will verify the prescription, confirm availability and pricing for your country, and arrange secure international shipping under the Named Patient Program. A valid prescription is mandatory before any order is processed.
🛡 Named Patient Program — Regulatory Framework
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.
This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.
Clinical References
- Finn RS, et al. Palbociclib and letrozole in advanced breast cancer (PALOMA-2). NEJM 2016;375:1925–1936.
- Cristofanilli M, et al. Fulvestrant plus palbociclib in HR-positive, HER2-negative advanced breast cancer (PALOMA-3). Lancet Oncol 2016;17:425–439.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V4.2026.
- Wander SA, et al. Mechanisms of resistance to CDK4/6 inhibitors in breast cancer. Cancer Discov 2020;10:1174–1193.
